Hossny Elham, Rosario Nelson, Lee Bee Wah, Singh Meenu, El-Ghoneimy Dalia, Soh Jian Yi, Le Souef Peter
Pediatric Allergy and Immunology Unit, Children's Hospital, Ain Shams University, Cairo, 11566 Egypt.
Federal University of Parana, Curitiba, Brazil.
World Allergy Organ J. 2016 Aug 12;9:26. doi: 10.1186/s40413-016-0117-0. eCollection 2016.
Despite the availability of several formulations of inhaled corticosteroids (ICS) and delivery devices for treatment of childhood asthma and despite the development of evidence-based guidelines, childhood asthma control remains suboptimal. Improving uptake of asthma management plans, both by families and practitioners, is needed. Adherence to daily ICS therapy is a key determinant of asthma control and this mandates that asthma education follow a repetitive pattern and involve literal explanation and physical demonstration of the optimal use of inhaler devices. The potential adverse effects of ICS need to be weighed against the benefit of these drugs to control persistent asthma especially that its safety profile is markedly better than oral glucocorticoids. This article reviews the key mechanisms of inhaled corticosteroid action; recommendations on dosage and therapeutic regimens; potential optimization of effectiveness by addressing inhaler technique and adherence to therapy; and updated knowledge on the real magnitude of adverse events.
尽管有多种吸入性糖皮质激素(ICS)制剂和给药装置可用于治疗儿童哮喘,尽管也制定了循证指南,但儿童哮喘的控制仍未达到最佳状态。有必要提高家庭和从业者对哮喘管理计划的接受程度。坚持每日ICS治疗是哮喘控制的关键决定因素,这就要求哮喘教育应采用重复模式,并包括对吸入器装置最佳使用方法的文字解释和实际演示。需要权衡ICS的潜在不良反应与这些药物控制持续性哮喘的益处,特别是因为其安全性明显优于口服糖皮质激素。本文综述了吸入性糖皮质激素作用的关键机制;关于剂量和治疗方案的建议;通过解决吸入技术和治疗依从性来潜在优化疗效;以及关于不良事件实际严重程度的最新知识。